Storia in 4 fonti

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 g fa

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

originale

Timeline cronologica

lunedì 3 agosto 2026·biopharmadive.com
Supernus, Individor merge to beef up brain drug portfolio
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and…
lunedì 3 agosto 2026·endpoints.news
Supernus, Indivior to merge and form CNS-focused drugmaker
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.

Supernus, Individor merge to beef up brain drug portfolio

Confronto fonti

Supernus, Individor merge to beef up brain drug portfolio

Timeline cronologica

Supernus, Individor merge to beef up brain drug portfolio

Supernus, Indivior to merge and form CNS-focused drugmaker

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Supernus, Indivior to merge and form CNS-focused drugmaker

Supernus, Indivior merge to create CNS-focused company and expand BD opportunities

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Supernus, Indivior merge to create CNS-focused company and expand BD opportunities